Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›
Research›
Government Agencies›
California Institute for Regenerative Medicine
AddedFeb 13, 2024
UpdatedJun 28, 2026
California Institute for Regenerative Medicine

California Institute for Regenerative Medicine

Operating

CIRM: A California-based research institute, established in 2004, specializing in stem cell research.

Founded
2005
Location
San Francisco, CA, US
Overview
Compare
Employees
Website

The California Institute for Regenerative Medicine (CIRM) is a state agency founded in 2004 following the approval of California Proposition 71 by 59% of voters. The initiative allocated $3 billion for stem cell research, with an additional fund approved in 2020 through Proposition 14. CIRM's core mission is to accelerate stem cell and gene therapy research to develop treatments and cures for serious diseases. The institute supports a wide range of activities, including funding clinical trials, research projects, and educational programs, primarily focusing on conditions such as cancer, diabetes, and rare diseases.

Notable affiliated individuals include Dr. Carolyn Meltzer, who serves on the CIRM Board. The institute has achieved significant milestones, including the establishment of Alpha Stem Cell Clinics and funding numerous clinical trials that have advanced the field of regenerative medicine. CIRM's impact is profound, having positioned California as a leader in stem cell research and contributing to global advancements in medical science.

Quick Facts

When was California Institute for Regenerative Medicine founded?

California Institute for Regenerative Medicine was founded in 2005.

Where is California Institute for Regenerative Medicine's headquarters located?

California Institute for Regenerative Medicine's headquarters is located in San Francisco, CA, US.

How many employees does California Institute for Regenerative Medicine have?

California Institute for Regenerative Medicine has 132 employees as of Feb 4, 2024.

Classification

Technology
  • Biotech
Revenue
  • Recurring
Customer
  • Government
  • Non-Profit
Main Product
  • Stem Cell Research
NAICS
  • 610000Educational Services
  • 611300Colleges, Universities, and Professional Schools
  • 611310Colleges, Universities, and Professional Schools
  • 611000Educational Services
SIC
  • 8220Colleges, Universities, Professional Schools, And Junior Colleges
  • 8221Colleges, Universities, And Professional Schools
  • 8200Educational Services
Show 13 more industry codes
NAICS
  • 922000Justice, Public Order, and Safety Activities
  • 922100Justice, Public Order, and Safety Activities
  • 922190Other Justice, Public Order, and Safety Activities
  • 620000Health Care and Social Assistance
  • 920000Public Administration
SIC
  • 9100Executive, Legislative, And General Government, Except Finance
  • 9200Justice, Public Order, And Safety
  • 9220Public Order And Safety
  • 9229Public Order And Safety, Not Elsewhere Classified
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8290Schools And Educational Services, Not Elsewhere Classified
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified